KYNTRA BIO, INC.

For the period ended Dec 31, 2025. Filed Mar 16, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 16, 2026

KYNB$3.90+4.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Statements of Operations

(In thousands, except per share amounts)

	Years Ended December 31,
	2025	2024
Revenue:
Development and other revenue	$592	$1,948
Drug product revenue, net	5,848	27,673
Total revenue	6,440	29,621
Operating costs and expenses:
Cost of goods sold	556	15,561
Research and development	23,517	95,692
Selling, general and administrative	27,709	49,330
Restructuring charge	553	19,454
Total operating costs and expenses	52,335	180,037
Loss from operations	(45,895)	(150,416)
Interest and other, net
Interest expense	(8,759)	(8,247)
Loss on debt extinguishments	(6,583)	—
Interest income and other income (expenses), net	2,943	5,296
Total interest and other, net	(12,399)	(2,951)
Loss from continuing operations before income taxes	(58,294)	(153,367)
Benefit from income taxes	(90)	(269)
Loss from continuing operations	(58,204)	(153,098)
Income from discontinued operations, net of tax	241,656	105,519
Net income (loss)	$183,452	$(47,579)
Loss from continuing operations per share - basic and diluted	$(14.40)	$(38.26)
Income from discontinued operations per share - basic and diluted	59.77	26.37
Net income (loss) per share - basic and diluted	$45.37	$(11.89)
Weighted average number of common shares used to calculate net income (loss) per share - basic and diluted	4,043	4,002

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.